AGOURON/JAPAN TOBACCO TARGETING ANTIVIRAL PROTEASE INHIBITORS
AGOURON/JAPAN TOBACCO TARGETING ANTIVIRAL PROTEASE INHIBITORS for treatment of hepatitis C, herpes and rhinovirus under an expanded R&D collaboration announced Feb. 28. "Agouron and JT will design compounds intended to inactivate protease enzymes known to be required for replication of hepatitis C, viruses in the herpes family, and the rhinoviruses responsible for common upper respiratory infections," Agouron said. The two firms are collaborating on design and development of immunosuppressants under a December 1992 agreement ("The Pink Sheet" Dec. 21, 1992, T&G-8).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth